Closed Automated Cell Manufacturing With Inline Quality Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing autologous cell therapies face high manufacturing costs and long turnaround times, making them inaccessible to many patients, and they can cause immune complications due to non-autologous cell therapies.

Innovation Solution

A closed, automated system for generating therapeutic cells that integrates cell isolation, gene integration, expansion, quality control, and product finishing, allowing for efficient, cost-effective, and rapid production of personalized cell therapies.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If traditional autologous cell therapy manufacturing processes are used, then personalized cell therapies can be produced, but manufacturing costs are high and turnaround times are long

Engineering Contradiction:

Improveturnaround timeVSAvoidmanufacturing time

Core Design Contradiction:

ProductivityVSLoss of time

Solution Approach 1:

The manufacturing system is divided into three independent modules: Module 1 for cell selection and genetic modification, Module 2 for cell expansion, and Module 3 for harvesting and formulation. This segmentation allows parallel processing and reduces overall manufacturing time while maintaining quality control at each stage.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The system performs preliminary cell selection and genetic modification in Module 1 before expansion, and conducts quality control assessments during the expansion phase in Module 2. This preliminary action ensures that only qualified cells are expanded, reducing rework and accelerating the overall process.

Inventive Principle:

Principle #10Preliminary action

2Productivity

If traditional cell therapy manufacturing is used, then therapeutic cells can be generated, but manufacturing costs are high

Engineering Contradiction:

Improvemanufacturing efficiencyVSAvoidmanufacturing cost

Core Design Contradiction:

ProductivityVSEase of manufacture

Solution Approach 1:

The system incorporates automated quality control that performs assessments and generates reports autonomously during the manufacturing process. The inline monitoring systems automatically detect and report deviations without manual intervention, reducing labor costs and improving efficiency.

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The system optimizes expansion conditions by dynamically adjusting parameters such as nutrient composition, pH, and oxygen levels during cell culture. This parameter optimization maximizes cell yield and quality while minimizing resource consumption and manufacturing costs.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If comprehensive quality control assays are performed, then cell therapy quality is ensured, but manufacturing time and complexity increase

Engineering Contradiction:

Improvecell therapy qualityVSAvoidsystem complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The system merges multiple quality control functions into integrated inline monitoring systems. Sensors simultaneously measure multiple parameters (pH, oxygen, cell density) and the system consolidates assay results into comprehensive quality reports, reducing the need for separate testing equipment and procedures.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The system implements real-time feedback through inline monitoring that continuously assesses cell quality parameters during manufacturing. This feedback mechanism allows immediate detection and correction of deviations, ensuring product quality without requiring complex post-manufacturing testing.

Inventive Principle:

Principle #23Feedback

4Productivity

If manual cell therapy manufacturing processes are used, then flexibility is maintained, but productivity and consistency are reduced

Engineering Contradiction:

Improvecell production efficiencyVSAvoidautomation level

Core Design Contradiction:

ProductivityVSExtent of automation

Solution Approach 1:

The automated system is designed with universal modules that can handle different cell types and therapeutic applications through programmable protocols. Module 1 can select and modify various cell types, Module 2 can expand different cell populations under optimized conditions, and Module 3 can formulate diverse cell products, providing flexibility without sacrificing automation benefits.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20250361472A1Systems, Methods, and Compositions for Generation of Therapeutic Cells

Publication Date: 2025.11.27 NATIONAL RESILIENCE LLC

AI summary

Systems, methods, and compositions can be used to generate a therapeutic cell. The system can be an fully closed, automated system. The system, methods and compositions can intake cells of a subject and modify the cells to generate therapeutic cells. Monitoring of the processes of the system and cells can be integrated into the system. Quality control metrics can be used to assess the quality of cells generated and assays to determine quality can be integrated and performed by the closed automated system.